PRMT5 Is an Actionable Therapeutic Target in CDK4/6 Inhibitor-Resistant ER+/RB-Deficient Breast Cancer

Through a genome-wide CRISPR screen, investigators identified protein arginine methyltransferase 5 (PRMT5) as a molecular vulnerability in ER+/RB1-knockout breast cancer cells.